peterlavi

info@peterlavi.com

About

Physician (MD) ・Stocks and ETFs investor ・10+ years of investing

・Keen on reading, reading and reading ・Writing on Forbes, SeekingAlpha, GuruFocus, and Yahoo Finance

peterlavi

This material is provided for informational purposes only and does not constitute investment advice. Trading financial instruments involves significant risks, including potential loss of capital.

Past performance is not a reliable indicator of future results.

Market prices fluctuate, dividends and returns are uncertain, and exchange rate movements may affect investments denominated in foreign currencies. Each individual must assess their risk tolerance accordingly. No universal investment formula exists, and no financial instrument is risk-free. The data used in this material is obtained from sources believed reliable, though accuracy cannot be guaranteed. Being an investor means assuming risk with the aim of achieving returns.

Your capital is at risk | Copy Trading does not amount to investment advice | Your investments value may go up or down

Investing is simple, but not easy

eToro - Pop Inv profile

www.peterlavi.com ©

- W. E. Buffett -

Welcome

This is an online space for anyone looking to dig deeper in my (peterlavi) analysis process.

Most content has been published also on: Forbes, SeekingAlpha, GuruFocus, LinkedIn, Yahoo Finance, and eToro.

TradingView

GuruFocus

YahooFinance

Forbes

916f95b48bd3a6f94d531f65d6140e8e63273c91

seekingAlpha

Invest via eToro platform

Grow your capital with us

This material is provided for informational purposes only and does not constitute investment advice. Trading financial instruments involves significant risks, including potential loss of capital.

Past performance is not a reliable indicator of future results.

Your capital is at risk | Copy Trading does not amount to investment advice | Your investments value may go up or down

DVA, davita, Forbes, financial analysis,

Forbes Published Our Analysis

Pietro Lavisci, MD

2025-08-14 12:46

Recently Forbes published the financial analysis I've written about DVA ( DaVita HealthCare Partners Inc ) , the leading US provider of kidney care services...

annual letter, cagr, 2024, peterlavi,

Lettera fine 2024 - Annual Letter

Pietro Lavisci, MD

2025-03-14 21:30

Don’t mistake possibilities for probabilities. Anything is possible. It’s the probabilities that matter. Everything must be weighed in terms of its likeliho

Valuation, VRTX, biotech, FDA approval, JOURNVAX, options strategy, options, long equity,

Vertex’s FDA Win: A Billion-Dollar Bet on Safer Pain Treatment

Pietro Lavisci, MD

2025-02-11 23:18

This biotech giant added to its solid drug portfolio the first major non-opioid drug approved in decades...

VRTX, biotechnology, momentum, FDA, biotech, pharma,

Biotech Brilliance: Vertex’s Quest to Redefine Non-Opioid Therapy

Pietro Lavisci, MD

2024-12-04 19:38

Let’s break down the buzz around Vertex, a company we valued earlier this year, and explore what’s driving its momentum...

GOOG, GOOGL, hedging, option, put,

Navigating GOOGL’s Legal Challenges: A Hedging Strategy for Alphabet Investors

Pietro Lavisci, MD

2024-12-01 22:19

This approach offers a defined risk profile and the potential for attractive returns or floor/protection against losses if the stock declines significantly...

Valuation, biotechnology, LLY,

From Sci-Fi Dream to Market Maze: Eli Lilly's Weight-Loss Medication Faces Hurdles - Jun 25, 2024

Pietro Lavisci, MD

2024-10-27 19:43

Assuming the rosier expectations will positively unfold, a reality check is done to compare the current valuation to informative financial ratios

Valuation, analysis, IBKR, broker-dealer, broker,

Meet Interactive Brokers, the Award-Winning Broker With Low Buzz - April 15, 2024

Pietro Lavisci, MD

2024-10-27 19:35

A tangled corporate structure should not scare investors out of this efficient multinational broker

Valuation, VRTX, biotechnology, analysis,

Vertex Is Worth Your Attention - April 03, 2024

Pietro Lavisci, MD

2024-10-27 19:30

The company's promising pipeline holds several catalysts in reserve outperformance in 2024

2023, Principles, Investing, annual letter, lettera fine, cagr, performance,

Lettera fine 2023 - Annual Letter

Pietro Lavisci, MD

2024-04-04 08:54

You don't have to be brilliant, only a little bit wiser than the other guys, on average, for a long, long, time. - Charles T. Munger

DCF, Valuation, Investing, AAPL, neutral,

AAPL Valuation

Pietro Lavisci, MD

2024-04-04 08:37

Apple Inc., strong cash cow performer, neutral valuation, hold your horses, for now..

META, DCF, Valuation, 2023,

META, Will the Rollercoaster Extend even Further?

Pietro Lavisci, MD

2023-09-06 06:14

DCF valuation on META based on most recent quarter numbers... will the ride extend further?

Long-Term Investments, Principles, Investing,

Long-Term Investing: Why Bother?

Pietro Lavisci, MD

2023-09-05 22:10

Don't know where to start investing? Let's read this quick text about the 5 essential investing principles...

Lettera fine 2022

Pietro Lavisci, MD

2023-04-04 21:37

2022 year-end letter to shareholders/investors/copiers

AMZN On Sale or In Trouble?

Pietro Lavisci, MD

2022-05-09 22:38

Considering five scenarios for AMZN valuation as FY 2021 financial results change the picture. In hindsight there were perhaps some evidence already..